Oral Pharmacotherapy for Benign Essential Blepharospasm
The disease course is generally progressive, especially during the initial years, with few patients ever achieving remission.2,4,5 Mainstay treatment options can be divided into three areas including management of sensory input, motor output, and central control. Although established treatment modalities have been identified and developed for the former two, central control of the disease has been more elusive for clinicians. Because the neuronal pathways of blinking have yet to be fully elucidated, drug therapy has proven to be challenging. Without a clear pharmacologic target, a variety of medications from a wide range of drug classes have been tried with varying success and associated side effect profiles. Treatment response to oral medication is typically characterized as partial, if any, resulting in individuals being tried on a variety of drugs.